Department of Surgical Oncology, Lanzhou University Second Hospital, Lanzhou 730000, China.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023 Feb 28;48(2):260-267. doi: 10.11817/j.issn.1672-7347.2023.220042.
Gastric cancer (GC) is one of the most common malignant tumors worldwide, and most of the patients are diagnosed at the advanced stage. Most of the treating options are comprehensive treatment, in which immunotherapy plays more and more important role. Melanoma antigen-associated gene-A (MAGE-A) family is a kind of cancer testis antigens. Except in germ cells of testis and trophoblast cells of placenta, MAGE-A family is highly expressed in cancerous tissues and participates in a variety of biological processes, such as cancer cell proliferation, differentiation and metastasis. In addition, cancer testis antigen also possesses good immunogenicity, which can induce humoral and cellular immune responses, is a good target for immunotherapy, and has good application value in the diagnosis, treatment and prognosis of GC. A variety of targeted therapeutic drugs based on MAGE-A are in phase I or II clinical trials, it has good safety and potential clinical application value. With the continuous progress of clinical trials and basic research on MAGE-A targets in GC, it is expected to provide a theoretical basis for clinical transformation and immunotherapy of MAGE-A in the future.
胃癌(GC)是全球最常见的恶性肿瘤之一,大多数患者在晚期被诊断出来。大多数治疗选择是综合治疗,其中免疫疗法发挥着越来越重要的作用。黑色素瘤相关抗原-A(MAGE-A)家族是一种癌睾丸抗原。除了睾丸生殖细胞和胎盘滋养层细胞外,MAGE-A 家族在癌组织中高度表达,并参与多种生物学过程,如癌细胞增殖、分化和转移。此外,癌睾丸抗原还具有良好的免疫原性,能诱导体液和细胞免疫应答,是免疫治疗的良好靶点,在 GC 的诊断、治疗和预后中有良好的应用价值。基于 MAGE-A 的各种靶向治疗药物正在进行 I 期或 II 期临床试验,具有良好的安全性和潜在的临床应用价值。随着对 GC 中 MAGE-A 靶点的临床试验和基础研究的不断进展,有望为未来 MAGE-A 的临床转化和免疫治疗提供理论依据。